Bellicum Pharmaceuticals Announces Appointment of Judith Klimovsky, M.D., to Board of Directors
December 20, 2018 07:00 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO
December 14, 2018 07:00 ET
|
Bellicum Pharmaceuticals, Inc.
Rimiducid-activated GoCAR-T® resulted in significant expansion and persistence of T cells Initial evidence of biologic activity and stable disease observed in some patients with single rimiducid dose...
Bellicum Pharmaceuticals Appoints Atabak Mokari as Chief Financial Officer
December 13, 2018 07:00 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Announces Data Presentation at ASH 2018 Demonstrating Low Rates of Cancer Recurrence in Pediatric AML and ALL Patients Treated with Rivo-cel
December 02, 2018 10:30 ET
|
Bellicum Pharmaceuticals, Inc.
SAN DIEGO, Dec. 02, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant
December 01, 2018 14:00 ET
|
Bellicum Pharmaceuticals, Inc.
Experience to date in clinical study shows high clinical response rates for patients with visceral GvHD or GvHD that was refractory to standard of care treatment SAN DIEGO, Dec. 01, 2018 (GLOBE...
Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018
December 01, 2018 12:00 ET
|
Bellicum Pharmaceuticals, Inc.
Interim results suggest rivo-cel outcomes were comparable to a control study of transplants from matched unrelated donors, a requirement for product registration in Europe Company on track to report...
Bellicum Pharmaceuticals to Host Analyst and Investor Event and Webcast on Monday, December 3
November 27, 2018 07:00 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals to Present at the Jefferies 2018 London Healthcare Conference
November 07, 2018 07:00 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 06, 2018 16:01 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Announces Data Presentations on Lead Product Candidate Rivo-cel and Controllable CAR Program at the 60th American Society of Hematology Annual Meeting
November 01, 2018 09:01 ET
|
Bellicum Pharmaceuticals, Inc.
Nine abstracts accepted, including two oral presentations HOUSTON, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable...